International Journal of Cardiology
Volume 127, Issue 1 , Pages 51-56 , 23 June 2008

Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study

  • Melinda Carrington
    • ,
  • Simon Stewart

      Affiliations

    • Corresponding Author InformationCorresponding author. Preventative Cardiology Baker Heart Research Institute PO Box 6492 St Kilda Rd Central Melbourne Vic 8008 Australia. Tel.: +61 3 9076 2903; fax: +61 3 9521 1837.

Received 18 January 2007 ,Accepted 1 April 2007.

References 

  1. Desprès J. Increasing high-density lipoprotein cholesterol: an update on fenofibrate. Int J Cardiol. 2001;88:30N–36N[suppl]
  2. Wierzbicki AS. FIELDS of dreams, fields of tears: a perspective on the fibrate trials. Int J Clin Pract. 2006;60(4):442–449
  3. Stewart S, Murphy N, McGuire A, McMurray JJV. The current cost of angina pectoris to the National Health Service in the United Kingdom. Heart. 2003;89:848–853
  4. The FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005;366(9500):1849–1861
  5. Perreault S, Hamilton VH, Lavoie F, Grover S. A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc Drugs Ther. 1996;10:787–794
  6. McMurray JJV, et al. for the CHARM investigators and committees Resource utilization and costs in the Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. Eur Heart J. 2006;27(12):1447–1458
  7. Stewart S, et al. for the COPERNICUS study group Carvedilol reduces the costs of medical care in severe heart failure: an economic analysis of the COPERNICUS study applied to the United Kingdom. Int J Cardiol. 2005;100:143–149
  8. Walker A, McMurray J, Stewart S, et al. Economic evaluation of the nicorandial in angina (IONA) trial in the UK and France. Heart. 2006;92:619–624
  9. Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost-effectiveness from multinational clinical trials. Health Econ. 1998;7:481–493
  10. Koopmanschap MA, Touw KCR, Rutten FFH. Analysis of costs and cost-effectiveness in multinational trials. Health Policy. 2001;58:175–186
  11. Health Economics of Statin (accessed December 2006). http://www.jr2.ox.ac.uk/bandolier/booth/cardiac/statecon.html.
  12. Yusuf S, Reddy S, Ounupuu S, et al. Global burden of cardiovascular diseases, part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. Circ. 2001;104:2855–2864
  13. Onupuu S, Negassa A, Yusuf S for the INTER-HEART Investigators. INTER-HEART: a global study of risk factors for acute myocardial infarction. Am Heart J. 2001;141:711–721
  14. Murphy NF, Stewart S, Hart CL, MacIntyre K, Hole D, McMurray JJV. A population study of the long-term consequences of Rose angina: 20-year follow-up of the Renfrew–Paisley study. Heart. 2006;92:1739–1746
  15. Heart Protection Study Collaborative Group. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from randomised trial of 20 536 people. BMJ. 2006;333:1145–1148
  16. Killilea T, Funk L. Cost efficiency and formulary considerations for statin therapy. Am J Manag Care. 2006;12:S325–S331
  17. Colhoun H. After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?. Lancet. 2005;366(9500):1829–1831
  18. Rosengren A, Wilhelmsen L, Hagman M, et al. Natural history of myocardial infarction and angina pectoris in a general population sample of middle-aged men: a 16-year follow-up of the Primary Prevention Study, Goteborg, Sweden. J Intern Med. 1998;244:495–505

PII: S0167-5273(07)00928-X

doi: 10.1016/j.ijcard.2007.04.040

International Journal of Cardiology
Volume 127, Issue 1 , Pages 51-56 , 23 June 2008

Article Tools

* Image Usage & Resolution